Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.
- Raised approximately A$2.13 million via U.S. at-the-market facility
- Expected A$5.69 million in Australian R&D tax rebates in Q1 2025
- Funding to accelerate clinical and business development of ATH434
- Positive topline Phase 2 results in Multiple System Atrophy (MSA)
- ATH434 holds Orphan Drug Designation from U.S. FDA and European Commission
Funding Boost Following Positive Phase 2 Results
Alterity Therapeutics (ASX:ATH, NASDAQ: ATHE) has successfully raised approximately A$2.13 million through its U.S.-based at-the-market (ATM) equity facility. This capital injection comes on the heels of encouraging topline data from the ATH434-201 Phase 2 clinical trial in Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder. The company also anticipates receiving around A$5.69 million in research and development tax rebates from the Australian Government’s R&DTI scheme in the first quarter of 2025.
Combined, these funds provide a significant financial runway for Alterity to accelerate both clinical and business development activities centered on ATH434, its lead oral therapeutic candidate targeting pathological protein aggregation implicated in neurodegeneration.
ATH434: A Promising Candidate in Neurodegenerative Disease
ATH434 operates as an iron chaperone, designed to restore normal iron balance in the brain and inhibit the aggregation of alpha-synuclein, a protein closely linked to Parkinsonian disorders. Preclinical studies have demonstrated its ability to reduce alpha-synuclein pathology and preserve neuronal function. The drug has already completed Phase 1 trials, confirming good tolerability and brain penetration at levels consistent with efficacy observed in animal models.
The recent Phase 2 trial in early-stage MSA patients yielded positive topline results, reinforcing ATH434’s potential as a disease-modifying treatment. A second Phase 2 open-label biomarker study targeting patients with more advanced MSA is currently underway, underscoring the company’s commitment to thorough clinical evaluation.
Strategic Implications and Regulatory Status
Importantly, ATH434 has been granted Orphan Drug Designation by both the U.S. Food and Drug Administration and the European Commission for the treatment of MSA. This status not only provides regulatory incentives but also highlights the unmet medical need in this therapeutic area.
With the fresh capital and expected tax rebates, Alterity is well-positioned to advance its clinical programs and engage in strategic business development initiatives, potentially including partnerships or licensing arrangements that could broaden ATH434’s reach.
CEO David Stamler emphasized the significance of the funding in enabling the company to maintain momentum following the encouraging Phase 2 data, signaling confidence in ATH434’s future prospects.
Looking Ahead
While the funding milestone is a positive development, the path forward remains contingent on the successful completion of ongoing clinical trials and regulatory approvals. Investors will be watching closely for detailed Phase 2 data releases and updates on the open-label study, which will provide deeper insights into ATH434’s therapeutic potential and safety profile.
Bottom Line?
Alterity’s fresh capital injection sets the stage for critical next steps in ATH434’s clinical journey, but clinical and regulatory hurdles remain ahead.
Questions in the middle?
- What detailed efficacy and safety data will emerge from the ongoing Phase 2 open-label biomarker trial?
- How will Alterity leverage its funding to expand business development or form strategic partnerships?
- What is the timeline and likelihood for ATH434’s regulatory approvals beyond Orphan Drug Designation?